These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

281 related items for PubMed ID: 12686333

  • 21. Abciximab, eptifibatide, and tirofiban: comparison of parenteral glycoprotein IIb/IIIa inhibitors.
    Dunn A.
    Conn Med; 1999 Aug; 63(8):483-7. PubMed ID: 10500344
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Frequency and outcomes of provisional glycoprotein IIb/IIIa blockade in patients receiving bivalirudin during percutaneous coronary intervention.
    Feldman DN, Wong SC, Bergman G, Minutello RM.
    J Invasive Cardiol; 2009 Jun; 21(6):258-63. PubMed ID: 19494400
    [Abstract] [Full Text] [Related]

  • 25. Meta-analysis of effectiveness and safety of abciximab versus eptifibatide or tirofiban in percutaneous coronary intervention.
    Brown DL, Fann CS, Chang CJ.
    Am J Cardiol; 2001 Mar 01; 87(5):537-41. PubMed ID: 11230835
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. An audit of the use and complications of glycoprotein IIb/IIIa inhibitors in percutaneous coronary intervention against national UK standards.
    Sheikh A, Baig K.
    Cardiovasc Revasc Med; 2006 Mar 01; 7(4):237-9. PubMed ID: 17174871
    [Abstract] [Full Text] [Related]

  • 31. Glycoprotein IIb/IIIa inhibitors during rescue percutaneous coronary intervention in acute myocardial infarction.
    Gruberg L, Suleiman M, Kapeliovich M, Hammerman H, Grenadier E, Boulus M, Amikam S, Markiewicz W, Beyar R.
    J Invasive Cardiol; 2006 Feb 01; 18(2):59-62. PubMed ID: 16446517
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Triple antiplatelet therapy during percutaneous coronary intervention is associated with improved outcomes including one-year survival: results from the Do Tirofiban and ReoProGive Similar Efficacy Outcome Trial (TARGET).
    Chan AW, Moliterno DJ, Berger PB, Stone GW, DiBattiste PM, Yakubov SL, Sapp SK, Wolski K, Bhatt DL, Topol EJ, TARGET Investigators.
    J Am Coll Cardiol; 2003 Oct 01; 42(7):1188-95. PubMed ID: 14522478
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Economic issues in glycoprotein IIb/IIIa receptor therapy.
    Hillegass WB, Newman AR, Raco DL.
    Am Heart J; 1999 Jul 01; 138(1 Pt 2):S24-32. PubMed ID: 10385788
    [Abstract] [Full Text] [Related]

  • 38. Trials of platelet glycoprotein IIb/IIIa receptor antagonists during percutaneous coronary revascularization.
    Lincoff AM.
    Am J Cardiol; 1998 Oct 22; 82(8B):36P-42P. PubMed ID: 9809890
    [Abstract] [Full Text] [Related]

  • 39. [The clinical use of the GPIIb/IIIa inhibitors eptifibatide and tirofiban in the treatment of acute coronary syndromes of the "non-ST elevation" type].
    Galli M, Maggioni AP, Vassanelli C, Tavazzi L.
    Ital Heart J Suppl; 2000 Feb 22; 1(2):202-11. PubMed ID: 10731377
    [Abstract] [Full Text] [Related]

  • 40. Long-term mortality after bolus-only administration of abciximab, eptifibatide, or tirofiban during percutaneous coronary intervention.
    Marmur JD, Poludasu S, Lazar J, Cavusoglu E.
    Catheter Cardiovasc Interv; 2009 Feb 01; 73(2):214-21. PubMed ID: 19156882
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 15.